How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cancer Angiogenesis Inhibitor Market
- By Product Type: Monoclonal Antibodies, Tyrosine Kinase Inhibitors (TKIs), mTOR Inhibitors, VEGF Inhibitors, Integrin Inhibitors
- By Indication: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Renal Cell Carcinoma, Breast Cancer, Glioblastoma
- By Mechanism of Action: VEGF Pathway Inhibitors, PDGF Pathway Inhibitors, FGF Pathway Inhibitors, Integrin Receptor Antagonists
- By Route of Administration: Intravenous Injection, Oral Administration
- By End User: Hospitals, Specialty Oncology Clinics, Ambulatory Surgical Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Monoclonal Antibodies leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Cancer Angiogenesis Inhibitor Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Indication 5
Mechanism of Action 4
Route of Administration 2
End User 3
Companies profiled
Roche Holding AG
Pfizer Inc.
Novartis AG
Eli Lilly and Company
Bristol-Myers Squibb Company
AstraZeneca plc
Merck & Co. Inc.
Sanofi S.A.
Bayer AG
Amgen Inc.
Regeneron Pharmaceuticals Inc.
Ipsen S.A.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bristol-Myers Squibb Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Regeneron Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ipsen S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Exelixis Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Seattle Genetics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BeiGene
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,956M by 2033 · 3.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Monoclonal Antibodies56.8
- Tyrosine Kinase Inhibitors (TKIs)11.3
- mTOR Inhibitors14.0
- VEGF Inhibitors7.1
- Integrin Inhibitors10.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,464M → $2,019M · 4.1%
Europe$1,021M → $1,381M · 3.9%
Asia Pacific$931.9M → $1,300M · 4.2%
Latin America$576.9M → $742.4M · 3.2%
Middle East and Africa$443.7M → $573.4M · 3.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.702026
3.722027
3.722028
3.732029
3.742030
3.762031
3.782032
3.792033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Holding AG10.3
- Pfizer Inc.18.2
- Novartis AG9.1
- Eli Lilly and Company10.0
- Bristol-Myers Squibb Company10.8
- AstraZeneca plc13.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type12.5%
Indication24.5%
Mechanism of Action30.2%
Route of Administration11.7%
End User21.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe23.0
- Asia Pacific21.6
- Latin America12.3
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Holding AG | 84 | 97 | 90 | 94 | 90 | 77 | 89 |
| Pfizer Inc. | 85 | 73 | 70 | 68 | 79 | 88 | 77 |
| Novartis AG | 74 | 82 | 70 | 68 | 73 | 70 | 73 |
| Eli Lilly and Company | 76 | 64 | 62 | 80 | 74 | 70 | 71 |
| Bristol-Myers Squibb Company | 64 | 65 | 52 | 64 | 52 | 62 | 60 |
| AstraZeneca plc | 47 | 67 | 68 | 65 | 46 | 60 | 59 |
| Merck & Co. Inc. | 57 | 45 | 43 | 47 | 61 | 52 | 51 |
| Sanofi S.A. | 56 | 37 | 55 | 58 | 36 | 43 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Holding AG
- Pfizer Inc.
- Novartis AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Holding AG | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Pfizer Inc. | ◐ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Novartis AG | ◐ | ✓ | − | ◐ | ✓ | − |
| Eli Lilly and Company | ◐ | ✓ | ◐ | ✓ | − | ◐ |
| Bristol-Myers Squibb Company | ◐ | ◐ | − | ◐ | − | ◐ |
| AstraZeneca plc | − | ◐ | ✓ | ◐ | − | − |
| Merck & Co. Inc. | ◐ | ◐ | ◐ | − | − | ◐ |
| Sanofi S.A. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Holding AG89
2Pfizer Inc.77
3Novartis AG73
4Eli Lilly and Company71
5Bristol-Myers Squibb Company60
6AstraZeneca plc59
7Merck & Co. Inc.51
8Sanofi S.A.48
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Roche Holding AG
Challenger3
Strong scale, closing on the leaders.
Pfizer Inc.Novartis AGEli Lilly and Company
Contender2
Focused players with pockets of strength.
Bristol-Myers Squibb CompanyAstraZeneca plc
Niche2
Specialists in a single segment or region.
Merck & Co. Inc.Sanofi S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Cancer Angiogenesis Inhibitor Market — a $126M beachhead inside a $2.03B market.
Beachhead (SOM)$126Mobtainable near-term
Serviceable (SAM)$709Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Monoclonal Antibodies
Best fit — highest urgency & budget in Product Type.
Economic buyer78 fit
Tyrosine Kinase Inhibitors (TKIs)
Strong fit — clear ROI and a fast path to value.
End user67 fit
mTOR Inhibitors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanism of Action
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel27%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cancer Angiogenesis Inhibitor Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified22%
Evaluation13%
Closed-won5%
$11.4KCAC
$54KLTV
4.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cancer Angiogenesis Inhibitor Market is a resilient opportunity — $2.15B by 2033, compounding at 4.5%.
TAM · 2025$1.52Btoday
TAM · 2033$2.15Bforecast
CAGR4.5%2027–2033
Cumulative$16.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.15BTotal addressable market
SAM$891MServiceable available market
SOM$158MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.5% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.15BLarge & growingTAM by 2033 at 4.5% CAGR
$891MServiceable nowreachable with today’s model
$158MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.68BBear2.9% CAGR
$2.15BBase4.5% CAGR
$2.75BBull5.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cancer Angiogenesis Inhibitor Market — a $2.47B market by 2033. Plan: grow share from 8.5% to 18.5%.
Market size · 2033$2.47Btotal addressable
Market CAGR6.0%2027–2033
Target share18.5%from 8.5% today
Revenue ambition$456Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 18.5% | On track |
| Revenue | $209M | $456M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.0% | 42.1% | On track |
| Customer retention | 89.0% | 94.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $67M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cancer Angiogenesis Inhibitor Market conversation — a $2.77B market you can size, segment and defend in minutes.
Market size · 2033$2.77Btotal opportunity
Growth9.7%CAGR to 2033
Addressable buyers1,271+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 4 mopayback period
$73K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Roche Holding AGPfizer Inc.Novartis AGEli Lilly and CompanyBristol-Myers Squibb CompanyAstraZeneca plcMerck & Co. Inc.Sanofi S.A.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cancer Angiogenesis Inhibitor Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cancer Angiogenesis Inhibitor Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cancer Biological Theraphy Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportCancer Biomaker Market
Market size, share, segmentation and regional forecast.
$352M market · 2025 base year
View reportCancer Cachexia Drug Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportCancer Care Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportCancer Cd Antigens Inhibitors Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCancer Cd Antigens Inhibitors Therapy Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportCancer Companion Diagnostic Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCancer Diagnostic Devices Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCancer Drug Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportCancer Gene Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportCancer Growth Inhibitors Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.